We are proud to announce the grant of our United States patent 12,285,433 B2, which protects the use of diltiazem as an activator of Interferon-λ (IFN-λ) expression for the prevention and/or treatment of microbial infections in human respiratory epithelia.

Our research has shown that diltiazem, a calcium channel blocker currently used to treat angina, induces a broad-spectrum antiviral state in human respiratory epithelia without triggering the inflammation commonly associated with type I and II interferons. Studies in reconstructed Human Airway Epithelium and mouse infection models demonstrated antiviral activity against Respiratory Syncytial Virus, Human Metapneumovirus, Human Parainfluenza Virus type 3, and Pseudomonas aeruginosa, highlighting its potential as a novel anti-infectious therapeutic agent.

This patent supports combination strategies to address resistance and microbial infections. With the granting of this new patent, we continue to expand our portfolio of host-targeted therapies designed to respond to seasonal and pandemic respiratory viral threats.

For more information, see patent and related publications:
https://lnkd.in/ebCZEkWr
https://lnkd.in/edMvs3Z6
https://lnkd.in/e4GSEpPE